High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers

被引:11
|
作者
Tokunaga, Eriko [1 ]
Okada, Satoko [1 ]
Yamashita, Nami [1 ]
Akiyoshi, Sayuri [1 ]
Kitao, Hiroyuki [2 ]
Morita, Masaru [1 ]
Kakeji, Yoshihiro [1 ]
Maehara, Yoshihiko [1 ]
机构
[1] Kyushu Univ, Dept Surg & Sci, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan
[2] Kyushu Univ, Dept Mol Oncol, Grad Sch Med Sci, Fukuoka 8128582, Japan
关键词
Loss of heterozygosity; Human epidermal receptor-2; Triple-negative breast cancer; Genetic instability; Breast cancer subtype; FLUORESCENT MICROSATELLITE ANALYSIS; DINUCLEOTIDE REPEAT INSTABILITY; DNA MISMATCH REPAIR; GENOME-WIDE SEARCH; PROGESTERONE-RECEPTOR; GASTRIC-CANCER; HETEROZYGOSITY; EXPRESSION; CARCINOMA; BRCA1;
D O I
10.1007/s12282-010-0232-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Basal-like and HER2-overexpressing breast carcinomas are histologically undifferentiated, high-grade tumors with a high proliferation rate and associated with a poor outcome. Most basal-like tumors lack the expression of ER, PR, and HER2 (triple-negative; TN). Loss of heterozygosity (LOH) is thought to reflect random chromosomal instability, and recent studies have shown that DNA-copy number alterations or LOH occur with a high frequency in basal-like and HER2-amplified tumors. The levels and patterns of LOH were analyzed by the microsatellite alteration analysis using fluorescence-labeled primers and an automated DNA sequencer at 5 randomly selected loci in 246 Japanese primary breast cancers. Associations between the level of LOH and breast cancer subtypes and tumor aggressiveness were investigated. The incidence and frequency of LOH was significantly higher in HER2 (56.3, 26.7%) and TN groups (44.4, 27.1%) than in luminal A (ER-positive and/or PR-positive and HER2-negative) groups (32.0, 12.2%). The incidence and frequency of LOH increased as nuclear grade was elevated. There were significantly more grade 3 tumors in the HER2 (80.0%) and TN (68.2%) subgroups (p < 0.0001). Even in HER2 and TN cases, the incidence and frequency of LOH was significantly higher in nuclear grade 3 cases than in grade 1 or 2 cases. Relapse-free survival of patients with LOH was significantly shorter than for those without LOH. In addition, the survival time was shorter as the frequency of LOH elevated. The incidence of LOH was an independent prognostic factor for relapse-free survival by multivariate analysis. High incidence and frequency of LOH, which indicate increased genetic instability, were found to be associated with the aggressive features of high-grade HER2 and TN breast cancers.
引用
收藏
页码:161 / 169
页数:9
相关论文
共 50 条
  • [41] HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer
    Shen, Sherry
    Ma, Weining
    Brown, David
    Paula, Arnaud Da Cruz
    Zhou, Qin
    Iaosonos, Alexia
    Tessier-Cloutier, Basile
    Ross, Dara S.
    Troso-Sandoval, Tiffany
    Reis-Filho, Jorge S.
    Abu-Rustum, Nadeem
    Zhang, Yanming
    Ellenson, Lora H.
    Weigelt, Britta
    Makker, Vicky
    Chui, M. Herman
    MODERN PATHOLOGY, 2023, 36 (11)
  • [42] Concomitant high expression of ERα36, EGFR and HER2 is associated with aggressive behaviors of papillary thyroid carcinomas
    Dai, Yu-Jie
    Qiu, Yi-Bo
    Jiang, Rong
    Xu, Man
    Zhao, Le
    Chen, George G.
    Liu, Zhi-Min
    SCIENTIFIC REPORTS, 2017, 7
  • [43] High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer
    Cao, Zhi-Gang
    Li, Jun-Jing
    Yao, Ling
    Huang, Yan-Ni
    Liu, Yi-Rong
    Hu, Xin
    Song, Chuan-Gui
    Shao, Zhi-Ming
    ONCOTARGET, 2016, 7 (40) : 64900 - 64909
  • [44] Replication-competent Herpes Simplex Virus Retargeted to HER2 as Therapy for High-grade Glioma
    Gambini, Eleonora
    Reisoli, Elisa
    Appolloni, Irene
    Gatta, Valentina
    Campadelli-Fiume, Gabriella
    Menotti, Laura
    Malatesta, Paolo
    MOLECULAR THERAPY, 2012, 20 (05) : 994 - 1001
  • [45] Magnetic Resonance Imaging Features in Triple-Negative Breast Cancer: Comparison With Luminal and HER2-Overexpressing Tumors
    Costantini, Melania
    Belli, Paolo
    Distefano, Daniela
    Bufi, Enida
    Di Matteo, Marialuisa
    Rinaldi, Pierluigi
    Giuliani, Michela
    Petrone, Gianluigi
    Magno, Stefano
    Bonomo, Lorenzo
    CLINICAL BREAST CANCER, 2012, 12 (05) : 331 - 339
  • [46] Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice
    Reisoli, E.
    Gambini, E.
    Appolloni, I.
    Gatta, V.
    Barilari, M.
    Menotti, L.
    Malatesta, P.
    CANCER GENE THERAPY, 2012, 19 (11) : 788 - 795
  • [47] Low Levels of High-Density Lipoprotein are Associated With Poor Prognosis in Patients With Early Triple-Negative Breast Cancer
    Liu, Yongcheng
    Wu, Di
    Wang, Huijuan
    Zheng, Heming
    CANCER CONTROL, 2024, 31
  • [48] HER2 Protein Overexpression and Gene Amplification in Tubo-Ovarian High-grade Serous Carcinomas
    Ersoy, Esma
    Cao, Qing Jackie
    Otis, Christopher N.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2022, 41 (04) : 313 - 319
  • [49] In ER-Positive, HER2-Negative Breast Cancers, HER2 mRNA Levels Correlate Better with Clinicopathologic Features and Oncotype DX Recurrence Score than HER2 Immunohistochemistry
    Tyburski, Haley
    Karakas, Cansu
    Finkelman, Brian S.
    Turner, Bradley M.
    Zhang, Huina
    Hicks, David G.
    LABORATORY INVESTIGATION, 2024, 104 (03)
  • [50] High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy
    Trere, D.
    Brighenti, E.
    Donati, G.
    Ceccarelli, C.
    Santini, D.
    Taffurelli, M.
    Montanaro, L.
    Derenzini, M.
    ANNALS OF ONCOLOGY, 2009, 20 (11) : 1818 - 1823